Brief: Simcere Pharmaceutical Says Phase 3 Study Of Sanbexin Sublingual Tablets Got Efficacy Endpoints
01/12/2022 14:32
Dec 1 (Reuters) - Simcere Pharmaceutical Group Ltd
2096.HK :
* PHASE III CLINICAL STUDY OF SANBEXIN SUBLINGUAL TABLETS
FOR
TREATMENT OF ACUTE ISCHEMIC STROKE GOT EXPECTED EFFICACY
ENDPOINTS
Source text for Eikon: ID:
Further company coverage: 2096.HK
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660